transplant-diagnostics
(2)
CareDx Made Transplant Care Less Invasive. Then Its Own Business Needed Surgery.
The transplant diagnostics company turned fragments of donor DNA into a recurring-care business. A 2023 reimbursement shock forced a reset - and revealed a playbook built on narrow markets, repeat tests, and one very deep customer relationship.
John Hanna
John W. Hanna is President and CEO of CareDx, Inc., the leading transplant patient diagnostics company based in Brisbane, California. Appointed in April 2024, he brings over two decades of executive leadership in molecular diagnostics and life sciences, including a decade at Veracyte and a stint as CEO of Apton Biosystems. At CareDx, he is executing a bold three-year plan targeting $500 million in revenue and 20% adjusted EBITDA by 2027, transforming the company from a single-test diagnostics business into a full clinical ecosystem for transplant centers worldwide.